Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Beijing 302 Hospital
Sponsor:
Information provided by (Responsible Party):
Fu-Sheng Wang, Beijing 302 Hospital
ClinicalTrials.gov Identifier:
NCT01690247
First received: September 19, 2012
Last updated: May 30, 2013
Last verified: May 2013
  Purpose

Liver transplantation is the only lifesaving intervention for patients with end-stage liver diseases. Despite the ability of current immunosuppressive agents to reduce the incidence of acute rejection, the rate of acute rejection reaches to 20-50% after liver transplantation. Furthermore, the long-term toxicity associated with current regimens for liver transplant recipients now is increasingly being perceived as an unmet clinical need. Mesenchymal stem cells (MSC) appeared to be effective in regulating the invoked immune response in setting such as tissue injury, transplantation, and autoimmunity, and have been used successfully to treat graft versus host disease and show immune modulation function both in vitro and in vivo and may help in repairing damaged tissue(s). Here, we evaluate umbilical cord derived MSC (UC-MSC) as an alternative immunosuppressive agents for liver transplanted patients, and examine if UC-MSC could improve the recovery of liver function.


Condition Intervention Phase
Evidence of Liver Transplantation
Drug: Conventional plus UC-MSC
Drug: Conventional plus placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Human Umbilical Cord Mesenchymal Stem Cell Induce Liver Allografts Tolerance

Resource links provided by NLM:


Further study details as provided by Beijing 302 Hospital:

Primary Outcome Measures:
  • Incidence rate of acute rejection and early liver function recovery [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Patient and graft survival, and prevalence of adverse events [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: February 2012
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Conventional plus UC-MSC
Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
Drug: Conventional plus UC-MSC
Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Other Name: Immunosuppressive agents plus umbilical cord stem cells
Placebo Comparator: Conventional plus placebo
Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
Drug: Conventional plus placebo
Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Other Name: Immunosuppressive agents plus saline

Detailed Description:

Liver transplantation is the only lifesaving intervention for patients with end-stage liver diseases. The current immunosuppressive agents reduce the incidence of acute cellular rejection; however, the rate of acute rejection reaches to 20-50% after liver transplantation. Furthermore, the long-term side effects of these regimens now has become a major challenge for liver transplant recipients and is increasingly being perceived as an unmet clinical need, for example, increases in the incidence of bacterial, viral infections, nephrotoxicity with chronic renal impairment, de novo diabetes mellitus, hyperlipidemia, arterial hypertension, cardiovascular disease, osteoporosis, neurotoxicity, hematological toxicity.

Mesenchymal stem cells (MSC) appeared to be effective in regulating the invoked immune response in setting such as tissue injury, transplantation, and autoimmunity, and have been used successfully to treat graft versus host disease and show immune modulation function both in vitro and in vivo and may help in repairing damaged tissue(s). Current clinical trails demonstrated that the use of autologous bone marrow MSC (BM-MSC) for renal transplanted patients resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function. Compared with BM-MSC, umbilical cord derived MSC (UC-MSC) may be the better choice for clinical application. One main reason is that the collection of BM-MSC from liver transplanted patients would be harmful for the patients. Moreover, the proliferative abilities of BM-MSC from patients with liver disease are deficient, whereas, UC-MSC can be obtained from discarded umbilical cords and can be produced on a larger scale. Our and other studies reported that the infusion of human UC-MSC are feasible and can improve liver function of liver fibrosis and liver failure.

The purpose of this study is to learn whether and how UC-MSC can improve the conditions in liver transplanted patients. This study will also look at how well UC-MSC is tolerated and its safety in liver transplanted patients.

Participants in the study will be randomly assigned to one of two treatment arms:

Arm A: Participants will receive 12 weeks of standard regular immunosuppressive agents plus UC-MSC treatment. Arm B: Participants will receive 12 weeks of standard regular immunosuppressive agents plus placebo. UC-MSC will be prepared according to standard procedures and is collected in plastic bags containing anti coagulant. MSCs are given via i.v. under sonography monitoring. After UC-MSC transfusion, patients are followed up at week 4, 8, 12, 24, 36 and 48, and the evaluation of liver function recovery was performed.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent.
  2. Patients must be between the ages of 18 and 70 years and meet the criteria for liver transplantation.
  3. Patient is receiving the first liver transplant.
  4. Patient is receiving a liver transplant only.
  5. Negative pregnancy test (female patients in fertile age).
  6. Willing to comply with the study visits.

Exclusion Criteria:

  1. Previously received or is receiving an organ transplant other than a liver.
  2. Vital organs failure (Cardiac, Renal or Respiratory, et al).
  3. Currently receiving an investigational drug or received an investigational drug within 30 days prior to transplant.
  4. Currently receiving any immunosuppressive agent.
  5. Clinically active bacterial, fungal, viral or parasitic infection.
  6. Pregnant or lactating women.
  7. Other candidates who are judged to be not applicable to this study by investigators.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01690247

Contacts
Contact: Fu-Sheng Wang, PHD 86-10-63879735 ext 2015.12 fswang302@163.com
Contact: Ming Shi, PHD 86-10-63879735 ext 2015.12 shiming302@sina.com

Locations
China
Beijing 302 Hospital Recruiting
Beijing, China, 100039
Contact: Fu-Sheng Wang, PHD    86-10-63879735 ext 2015.12    fswang302@163.com   
Contact: Ming Shi, PHD    86-10-63879735 ext 2015.12    shiming302@sina.com   
Principal Investigator: Fu-Sheng Wang, PHD         
Sub-Investigator: Zhenwen Liu, Doctor         
Sub-Investigator: Ming Shi, PHD         
Sponsors and Collaborators
Beijing 302 Hospital
Investigators
Principal Investigator: Fu-Sheng Wang, PHD Beijing 302 Hospital
  More Information

Publications:

Responsible Party: Fu-Sheng Wang, Research Center for Biotherapy, Beijing 302 Hospital
ClinicalTrials.gov Identifier: NCT01690247     History of Changes
Other Study ID Numbers: Beijing302-008
Study First Received: September 19, 2012
Last Updated: May 30, 2013
Health Authority: China: Ministry of Health

Keywords provided by Beijing 302 Hospital:
mesenchymal stem cells
liver transplantation
clinical trial
rejection

Additional relevant MeSH terms:
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014